| Autor: |
Watanabe, Hideomi, Inoue, Tomio, Shinozaki, Tetsuya, Yanagawa, Takashi, Ahmed, Adel Refaat, Tomiyoshi, Katsumi, Oriuchi, Noboru, Tokunaga, Mari, Aoki, Jun, Endo, Keigo, Takagishi, Kenji |
| Předmět: |
|
| Zdroj: |
European Journal of Nuclear Medicine; 2000, Vol. 27 Issue 10, p1509-1517, 9p |
| Abstrakt: |
Abstract. Fluorine-18 labelled alpha-methyltyrosine (FMT) was developed for positron emission tomography (PET) imaging, and its potential for clinical application in patients with brain tumours has been demonstrated. This is the first trial to compare FMT with [sup 18]F-fluoro-2-deoxy-D-glucose (FDG) for the evaluation of musculoskeletal tumours. Seventy-five patients were examined with both FMT- and FDG-PET within a 2-week period. Imaging findings were visually inspected in conjunction with computed tomography and/or magnetic resonance imaging, and standardized uptake values (SUVs) for both FMT and FDG in lesions were also generated and compared with histological findings. A significant correlation between FMT and FDG SUVs was found for all lesions (r = 0.769, P<0.0001), and mean values for malignant tumours were significantly higher than those for benign lesions in both FMT- and FDG-PET. The diagnostic sensitivities and specificities for malignancy were 72.7% and 84.9%, respectively, using FMT with a cut-off SUV of 1.2, and 72.7% and 66.0%, respectively, using FDG with a cut-off SUV of 1.9. The resultant accuracy with FMT was 81.3%, higher than that for FDG (68.0%), and the difference with respect to specificity was significant (chi[sup 2] cal = 5.0625, P<0.05). On the... [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
